Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

18th International Meeting of the European Society of Gynaecological Oncology (ESGO) /
Molecular profiling of primary compared to metastatic lesion in gynaecologic cancers

19th - 22nd Oct 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 31.10.13
Views: 10397
Rating:

Prof Helga Birgitte Salvesen - University of Bergen, Norway

Prof Helga Birgitte Salvesen talks to ecancer at the 2013 ESGO meeting in Liverpool about the molecular profiling of endometrial tumours. Prof Salvesen stresses that there is a need to increase the knowledge on what the key targets are for clinical trials. One potentially drugable candidate being studied is the PI3 kinase in aggressive disease. Other issues arising from clinical data are prognostic markers in primary tumours versus those present in metastatic disease.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation